1. Home
  2. ZION vs CYTK Comparison

ZION vs CYTK Comparison

Compare ZION & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zions Bancorporation N.A.

ZION

Zions Bancorporation N.A.

N/A

Current Price

$71.37

Market Cap

9.4B

Sector

Finance

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$76.44

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZION
CYTK
Founded
1873
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4B
10.7B
IPO Year
2012
2004

Fundamental Metrics

Financial Performance
Metric
ZION
CYTK
Price
$71.37
$76.44
Analyst Decision
Hold
Strong Buy
Analyst Count
18
19
Target Price
$65.33
$89.26
AVG Volume (30 Days)
1.5M
1.8M
Earning Date
04-20-2026
05-05-2026
Dividend Yield
2.88%
N/A
EPS Growth
21.41
N/A
EPS
4.61
N/A
Revenue
$662,000,000.00
$13,368,000.00
Revenue This Year
$8.57
$7.37
Revenue Next Year
$4.67
$310.19
P/E Ratio
$15.53
N/A
Revenue Growth
3.60
N/A
52 Week Low
$46.21
$35.22
52 Week High
$73.34
$88.31

Technical Indicators

Market Signals
Indicator
ZION
CYTK
Relative Strength Index (RSI) 54.27 43.60
Support Level $67.89 $73.95
Resistance Level $71.26 $80.65
Average True Range (ATR) 1.21 2.98
MACD -0.01 -0.42
Stochastic Oscillator 61.70 32.54

Price Performance

Historical Comparison
ZION
CYTK

About ZION Zions Bancorporation N.A.

Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: